PRC-4016

DRUG2 trials

Sponsors

Pronova BioPharma

Conditions

Dyslipidemia

Phase 2

The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects

CompletedNCT01893515

Pronova BioPharmaDyslipidemia

Start: 2013-07-31End: 2014-07-31Updated: 2015-10-30

Efficacy and Safety of PRC-4016 in Subjects With Mixed Dyslipidemia

TerminatedNCT01972178

Pronova BioPharmaDyslipidemia

Start: 2013-11-30End: 2014-08-31Updated: 2015-10-30

Related Papers

Icosabutate for the treatment of very high triglycerides: A placebo-controlled, randomized, double-blind, 12-week clinical trial.

2015-11-1423 citations